Castle Biosciences, Inc. - Common stock (NQ:CSTL)

23.13 -0.30 (-1.28%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Price and Volume

Volume	443,673
Open	23.30
Bid (Size)	22.00 (16,800)
Ask (Size)	26.00 (100)
Prev. Close	23.43
Today's Range	21.79 - 23.33
52wk Range	14.59 - 44.28
Shares Outstanding	25,167,365
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

March 13, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

March 09, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	-40.0%	-40.0%
1 Month	-13.0%	-13.0%
3 Month	-42.0%	-42.0%
6 Month	-2.2%	-2.2%
1 Year	+15.0%	+15.0%

More News

This $56 Million Sale Slashed One Fund's DigitalBridge Stake Amid 49% Stock Surge ↗

March 05, 2026

Via The Motley Fool

This Fund Just Disclosed a $29 Million Sale of a Beauty Stock Up 20% This Past Year ↗

March 05, 2026

Via The Motley Fool

Castle Biosciences Inc (NASDAQ:CSTL) Reports Q4 2025 Revenue Beat Amid Profitability Transition ↗

February 26, 2026

Via Chartmill

What's Behind This $32 Million Bet on Baidu Amid a 36% Stock Rally? ↗

March 05, 2026

Via The Motley Fool

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

March 04, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

March 03, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences (CSTL) Earnings Transcript ↗

February 26, 2026

Via The Motley Fool

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 26, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

February 19, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

February 05, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗

February 03, 2026

Via The Motley Fool

AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗

February 02, 2026

Via The Motley Fool

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

January 11, 2026

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

December 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

December 12, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

December 09, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

November 17, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

November 14, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

November 11, 2025

From Castle Biosciences, Inc.

Via GlobeNewswire

Why Castle Biosciences' Rally Might Just Be Getting Started ↗

November 05, 2025

Via Benzinga

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?

Yes, Castle Biosciences, Inc. - Common stock is publicly traded.

What exchange does Castle Biosciences, Inc. - Common stock trade on?

Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Castle Biosciences, Inc. - Common stock?

The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market

What is the current price of Castle Biosciences, Inc. - Common stock?

The current price of Castle Biosciences, Inc. - Common stock is 23.13

When was Castle Biosciences, Inc. - Common stock last traded?

The last trade of Castle Biosciences, Inc. - Common stock was at 04/10/26 04:00 PM ET

What is the market capitalization of Castle Biosciences, Inc. - Common stock?

The market capitalization of Castle Biosciences, Inc. - Common stock is 582.12M

How many shares of Castle Biosciences, Inc. - Common stock are outstanding?

Castle Biosciences, Inc. - Common stock has 582M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.